P. Cassier, F. Ducimetière, A. Lurkin, D. Ranchère-vince, and J. Scoazec, A prospective epidemiological study of new incident GISTs during two consecutive years in Rh?ne Alpes region: incidence and molecular distribution of GIST in a European region, British Journal of Cancer, vol.25, issue.2, pp.165-170, 2010.
DOI : 10.1002/cncr.20862

M. Heinrich, C. Corless, A. Duensing, L. Mcgreevey, and C. Chen, PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors, Science, vol.299, issue.5607, pp.708-710, 2003.
DOI : 10.1126/science.1079666

S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, and T. Nishida, Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors, Science, vol.279, issue.5350, pp.577-580, 1998.
DOI : 10.1126/science.279.5350.577

B. Rubin, M. Heinrich, and C. Corless, Gastrointestinal stromal tumour, The Lancet, vol.369, issue.9574, pp.1731-1741, 2007.
DOI : 10.1016/S0140-6736(07)60780-6

J. Bachet, I. Hostein, L. Cesne, A. Brahimi, S. Beauchet et al., Prognosis and predictive value of KIT exon 11 deletion in GISTs, British Journal of Cancer, vol.6, issue.1, pp.7-11, 2009.
DOI : 10.1002/ijc.11323

C. Corless, J. Fletcher, and M. Heinrich, Biology of Gastrointestinal Stromal Tumors, Journal of Clinical Oncology, vol.22, issue.18, pp.3813-3825, 2004.
DOI : 10.1200/JCO.2004.05.140

J. Emile, N. Théou, S. Tabone, A. Cortez, and P. Terrier, Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors, Clinical Gastroenterology and Hepatology, vol.2, issue.7, pp.597-605, 2004.
DOI : 10.1016/S1542-3565(04)00243-5

C. Blanke, C. Rankin, G. Demetri, C. Ryan, and M. Von-mehren, Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033, Journal of Clinical Oncology, vol.26, issue.4, pp.626-632, 2008.
DOI : 10.1200/JCO.2007.13.4452

R. Dematteo, K. Ballman, C. Antonescu, R. Maki, and P. Pisters, Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial, The Lancet, vol.373, issue.9669, pp.1097-1104, 2009.
DOI : 10.1016/S0140-6736(09)60500-6

J. Verweij, P. Casali, J. Zalcberg, A. Lecesne, and P. Reichardt, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, The Lancet, vol.364, issue.9440, pp.1127-1134, 2004.
DOI : 10.1016/S0140-6736(04)17098-0

M. Debiec-rychter, R. Sciot, L. Cesne, A. Schlemmer, M. Hohenberger et al., KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours, European Journal of Cancer, vol.42, issue.8, pp.1093-1103, 2006.
DOI : 10.1016/j.ejca.2006.01.030

M. Heinrich, C. Corless, G. Demetri, C. Blanke, and M. Von-mehren, Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, Journal of Clinical Oncology, vol.21, issue.23, pp.4342-4349, 2003.
DOI : 10.1200/JCO.2003.04.190

J. Emile, J. Bachet, S. Tabone-eglinger, P. Terrier, and J. Vignault, GIST with homozygous KIT exon 11 mutations, Laboratory Investigation, vol.1688, issue.5, pp.456-457, 2008.
DOI : 10.1097/00000478-200604000-00008

J. Lasota, A. Dobosz, B. Wasag, A. Wozniak, and E. Kraszewska, Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors, Laboratory Investigation, vol.1741, issue.10, pp.1029-1041, 2007.
DOI : 10.1038/labinvest.3700628

M. Wallander, C. Willmore-payne, and L. Layfield, C-KIT and PDGFRA Zygosity in Gastrointestinal Stromal Tumors, Applied Immunohistochemistry & Molecular Morphology, vol.19, issue.1, pp.21-27, 2011.
DOI : 10.1097/PAI.0b013e3181ec4f95

P. Blume-jensen, L. Claesson-welsh, A. Siegbahn, K. Zsebo, and B. Westermark, Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis, EMBO J, vol.10, pp.4121-4128, 1991.

C. Mol, D. Dougan, T. Schneider, R. Skene, and M. Kraus, Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase, Journal of Biological Chemistry, vol.279, issue.30, pp.31655-31663, 2004.
DOI : 10.1074/jbc.M403319200

R. Roskoski, Structure and regulation of Kit protein-tyrosine kinase???The stem cell factor receptor, Biochemical and Biophysical Research Communications, vol.338, issue.3, pp.1307-1315, 2005.
DOI : 10.1016/j.bbrc.2005.09.150

S. Tabone-eglinger, F. Subra, E. Sayadi, H. Alberti, L. Tabone et al., KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors, Clinical Cancer Research, vol.14, issue.8, pp.2285-2294, 2008.
DOI : 10.1158/1078-0432.CCR-07-4102
URL : https://hal.archives-ouvertes.fr/hal-00283136

Z. Xiang, F. Kreisel, J. Cain, A. Colson, and M. Tomasson, Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling, Molecular and Cellular Biology, vol.27, issue.1, pp.267-282, 2007.
DOI : 10.1128/MCB.01153-06
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800644

S. Brahimi-adouane, J. Bachet, S. Tabone-eglinger, F. Subra, and C. Capron, Effects of endoplasmic reticulum stressors on maturation and signaling of?hemizygous and heterozygous wild-type and mutant forms of KIT, Molecular Oncology, vol.116, issue.3, 2012.
DOI : 10.1016/j.molonc.2012.10.008

N. Casteran, D. Sepulveda, P. Beslu, N. Aoubala, M. Letard et al., Signal transduction by several KIT juxtamembrane domain mutations, Oncogene, vol.22, issue.30, pp.4710-4722, 2003.
DOI : 10.1038/sj.onc.1206587

W. Pear, J. Miller, L. Xu, J. Pui, and B. Soffer, Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow, Blood, vol.92, pp.3780-4003, 1998.

J. Emile, A. Lemoine, N. Bienfait, P. Terrier, and D. Azoulay, Length Analysis of Polymerase Chain Reaction Products: A Sensitive and Reliable Technique for the Detection of Mutations in KIT Exon 11 in Gastrointestinal Stromal Tumors, Diagnostic Molecular Pathology, vol.11, issue.2, pp.107-112, 2002.
DOI : 10.1097/00019606-200206000-00007

A. Gougelet, J. Perez, D. Pissaloux, A. Besse, and A. Duc, miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas, Sarcoma, vol.2, issue.6, p.460650, 2011.
DOI : 10.1073/pnas.0804549105
URL : https://hal.archives-ouvertes.fr/hal-00824176

P. Casali, L. Jost, P. Reichardt, M. Schlemmer, and J. Blay, Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up, Annals of Oncology, vol.19, issue.Supplement 2, pp.35-43, 2008.
DOI : 10.1093/annonc/mdn080

B. Rubin, C. Antonescu, J. Scott-browne, M. Comstock, and Y. Gu, A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E, Cancer Research, vol.65, issue.15, pp.6631-6639, 2005.
DOI : 10.1158/0008-5472.CAN-05-0891

G. Sommer, V. Agosti, I. Ehlers, F. Rossi, and S. Corbacioglu, Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase, Proceedings of the National Academy of Sciences, vol.347, issue.7, pp.6706-6711, 2003.
DOI : 10.1056/NEJMoa020461

G. Liang, G. Bansal, Z. Xie, and K. Druey, RGS16 Inhibits Breast Cancer Cell Growth by Mitigating Phosphatidylinositol 3-Kinase Signaling, Journal of Biological Chemistry, vol.284, issue.32, pp.21719-21727, 2009.
DOI : 10.1074/jbc.M109.028407
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755894

J. Kim, J. Lee, K. Lee, J. Lee, and K. Lee, RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression, Tumor Biology, vol.11, issue.5, pp.541-548, 2010.
DOI : 10.1007/s13277-010-0067-z

R. Ceder, Y. Haig, M. Merne, A. Hansson, and X. Zheng, Differentiation-Promoting Culture of Competent and Noncompetent Keratinocytes Identifies Biomarkers for Head and Neck Cancer, The American Journal of Pathology, vol.180, issue.2, pp.457-472, 2012.
DOI : 10.1016/j.ajpath.2011.10.016

S. Mok, T. Bonome, V. Vathipadiekal, A. Bell, and M. Johnson, A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2, Cancer Cell, vol.16, issue.6, pp.521-532, 2009.
DOI : 10.1016/j.ccr.2009.10.018

A. Dumont, Y. Yang, D. Reynoso, D. Katz, and J. Trent, Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors, Carcinogenesis, vol.33, issue.9, pp.1674-1683, 2012.
DOI : 10.1093/carcin/bgs221

A. Albig, D. Becenti, T. Roy, and W. Schiemann, Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells, Microvascular Research, vol.76, issue.1, pp.7-14, 2008.
DOI : 10.1016/j.mvr.2008.01.001

S. De-renzis, B. Sönnichsen, and M. Zerial, Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomes, Nature Cell Biology, vol.4, issue.2, pp.124-133, 2002.
DOI : 10.1038/ncb744

G. Yan, S. Xu, Z. Tan, L. Liu, and Q. He, Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics, PROTEOMICS, vol.105, issue.5, pp.912-920, 2011.
DOI : 10.1002/pmic.201000539

V. Goebeler, M. Poeter, D. Zeuschner, V. Gerke, and U. Rescher, Annexin A8 Regulates Late Endosome Organization and Function, Molecular Biology of the Cell, vol.19, issue.12, pp.5267-5278, 2008.
DOI : 10.1091/mbc.E08-04-0383
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592647

Z. Karanjawala, P. Illei, R. Ashfaq, J. Infante, and K. Murphy, New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8, The American Journal of Surgical Pathology, vol.32, issue.2, pp.188-196, 2008.
DOI : 10.1097/PAS.0b013e31815701f3

M. Berthouze, V. Venkataramanan, Y. Li, and S. Shenoy, The deubiquitinases USP33 and USP20 coordinate ?2 adrenergic receptor recycling and resensitization, The EMBO Journal, vol.47, issue.12, pp.1684-1696, 2009.
DOI : 10.1074/jbc.M707009200

R. Buus, M. Faronato, D. Hammond, S. Urbé, and M. Claque, Deubiquitinase Activities Required for Hepatocyte Growth Factor-Induced Scattering of Epithelial Cells, Current Biology, vol.19, issue.17, pp.1463-1466, 2009.
DOI : 10.1016/j.cub.2009.07.040

G. Lind, S. Danielsen, T. Ahlquist, M. Merok, and K. Andresen, Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas, Molecular Cancer, vol.10, issue.1, p.85, 2011.
DOI : 10.1186/gb-2008-9-9-r139

Y. Wang, Q. Yu, A. Cho, G. Rondeau, and J. Welsh, Survey of Differentially Methylated Promoters in Prostate Cancer Cell Lines, Neoplasia, vol.7, issue.8, pp.748-760, 2005.
DOI : 10.1593/neo.05289

M. Davidson, J. Larsen, I. Yang, N. Hayward, and B. Clarke, MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma, PLoS ONE, vol.170, issue.9, p.12560, 2010.
DOI : 10.1371/journal.pone.0012560.s014

A. Denk, S. Braig, T. Schubert, and A. Bosserhoff, Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells, Int J Mol Med, vol.28, pp.721-726, 2011.

S. Banerjee, G. Dhar, I. Haque, S. Kambhampati, and S. Mehta, CCN5/WISP-2 Expression in Breast Adenocarcinoma Is Associated with Less Frequent Progression of the Disease and Suppresses the Invasive Phenotypes of Tumor Cells, Cancer Research, vol.68, issue.18, pp.7606-7612, 2008.
DOI : 10.1158/0008-5472.CAN-08-1461

S. Davies, M. Davies, A. Sanders, C. Parr, and J. Torkington, Differential expression of the CCN family member WISP-1, WISP-2 and WISP- 3 in human colorectal cancer and the prognostic implications, Int J Oncol, vol.36, pp.1129-1136, 2010.

R. Haydon, A. Deyrup, A. Ishikawa, R. Heck, and W. Jiang, Cytoplasmic and/or nuclear accumulation of the ?-catenin protein is a frequent event in human osteosarcoma, International Journal of Cancer, vol.98, issue.4, pp.338-342, 2002.
DOI : 10.1002/ijc.10719

C. Hou, Y. Chiang, Y. Fong, and C. Tang, WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells, Biochemical Pharmacology, vol.81, issue.11, pp.1286-1295, 2011.
DOI : 10.1016/j.bcp.2011.03.016

Y. Nagai, M. Watanabe, S. Ishikawa, R. Karashima, and J. Kurashige, Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma, Anticancer Res, vol.31, pp.991-997, 2011.

H. Clevers, Wnt/?-Catenin Signaling in Development and Disease, Cell, vol.127, issue.3, pp.469-480, 2006.
DOI : 10.1016/j.cell.2006.10.018

S. Vijayakumar, G. Liu, I. Rus, S. Yao, and Y. Chen, High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/??-Catenin Target Gene, CDC25A, Cancer Cell, vol.19, issue.5, pp.601-612, 2011.
DOI : 10.1016/j.ccr.2011.03.010

J. Bachet and J. Emile, Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors, The Application Of Clinical Genetics, vol.3, pp.85-101, 2010.

S. Jiang, Y. Li, Y. Zhu, X. Wu, and J. Tanq, Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma, Cancer Science, vol.8, issue.8, pp.1568-1575, 2011.
DOI : 10.1111/j.1349-7006.2011.01964.x

C. Haferlach, U. Bacher, T. Haferlach, F. Dicker, and T. Alpermann, The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML, Leukemia, vol.25, issue.5, pp.874-877, 2011.
DOI : 10.1080/10428190701632848

J. Lennartsson, P. Blume-jensen, M. Hermanson, E. Pontén, and M. Carlberg, Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction, Oncogene, vol.18, issue.40, pp.5546-5553, 1999.
DOI : 10.1038/sj.onc.1202929

K. Masson, E. Heiss, H. Band, and L. Rönnstrand, of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation, Biochemical Journal, vol.399, issue.1, pp.59-67, 2006.
DOI : 10.1042/BJ20060464
URL : https://hal.archives-ouvertes.fr/hal-00478567

D. Price, B. Rivnay, Y. Fu, S. Jiang, and S. Avraham, Direct Association of Csk Homologous Kinase (CHK) with the Diphosphorylated Site Tyr568/570 of the Activated c-KIT in Megakaryocytes, Journal of Biological Chemistry, vol.272, issue.9, pp.5915-5920, 1997.
DOI : 10.1074/jbc.272.9.5915

I. Timokhina, H. Kissel, G. Stella, and P. Besmer, Kit signaling through PI3- kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation, EBMO J, vol.17, pp.6250-6262, 1998.

P. Wollberg, J. Lennartsson, E. Gottfridsson, A. Yoshimura, and L. Rönnstrand, The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit, Biochemical Journal, vol.370, issue.3, pp.1033-1038, 2003.
DOI : 10.1042/bj20020716

M. Kozlowski, L. Larose, F. Lee, D. Le, and R. Rottapel, SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain, Molecular and Cellular Biology, vol.18, issue.4, pp.2089-2099, 1998.
DOI : 10.1128/MCB.18.4.2089

R. Shivakrupa and D. Linnekin, Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells, Cellular Signalling, vol.17, issue.1, pp.103-109, 2005.
DOI : 10.1016/j.cellsig.2004.06.004

S. Scholl, C. Kirsch, F. Böhmer, and R. Klinger, Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells, Journal of Cancer Research and Clinical Oncology, vol.32, issue.12, pp.711-718, 2004.
DOI : 10.1007/s00432-004-0602-7

J. Emile, N. Stock, C. Corless, R. Sciot, and H. Schildhaus, Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs, The American Journal of Surgical Pathology, vol.33, issue.1, pp.157-158, 2009.
DOI : 10.1097/PAS.0b013e3181883765

M. Heinrich, K. Owzar, C. Corless, D. Hollis, and E. Borden, Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group, Journal of Clinical Oncology, vol.26, issue.33, pp.5360-5367, 2008.
DOI : 10.1200/JCO.2008.17.4284